Key result
Thyromimetics show promise as a potential strategy to lower cholesterol and triglycerides in combined hyperlipidemia.
Why the study?
Atherosclerosis remains the leading cause of death, and novel liver- and thyroid hormone receptor β-selective analogs like sobetirome offer a new approach to treat dyslipidemia, a major cardiovascular risk factor.
Answers are grounded in this paper and cite their sources.
Atherosclerosis and its clinical sequelae still represent the primary cause of death in Western societies. During the past 25 years, a novel drug class to treat dyslipidemia, a main risk factor for coronary artery disease, emerged: liver- and thyroid hormone receptor isoform β-selective analogs. The present review will discuss the recent patents applied for sobetirome (GC-1), which set the course for the establishment of a novel approach to lower plasma cholesterol and triglycerides. We will focus on the major mechanisms conferring sobetirome lipid-lowering properties, including the induction of hepatic LDL receptor, the promotion of the so-called reverse cholesterol transport, and finally the induction of bile acid production and biliary sterol secretion. In summary, thyromimetics such as sobetirome may represent a useful treatment for combined hyperlipidemia, which is associated with a major cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Tancevski et al. (2011) conducted a review in Dyslipidemia. Sobetirome was evaluated. Thyromimetics such as sobetirome represent a potentially useful treatment approach for lowering plasma cholesterol and triglycerides in combined hyperlipidemia.
Synapse has enriched 10 related papers. Consider them for comparative context: